Regeneron Pharmaceuticals (REGN) Non-Current Assets (2009 - 2026)

Regeneron Pharmaceuticals' Non-Current Assets history runs 18 years deep, the most recent figure standing at $23.3 billion for Q2 2026.

• In Q2 2026, Non-Current Assets rose 9.01% year-over-year to $23.3 billion; the TTM figure through Jun 2026 stood at $90.7 billion (up 15.44% YoY), while the FY2025 annual figure was $22.5 billion, up 18.0% from the prior year.
• Non-Current Assets for Q2 2026 stood at $23.3 billion, up from $22.7 billion in the prior quarter.
• The five-year high for Non-Current Assets was $23.3 billion in Q2 2026, with the low at $11.7 billion in Q2 2022.
• The 5-year median for Non-Current Assets is $16.3 billion (2024), against an average of $16.9 billion.
• The sharpest annual moves came in 2022 and 2023: Non-Current Assets soared 56.05% in 2022, then advanced 2.03% in 2023.
• Regeneron Pharmaceuticals' Non-Current Assets stood at $13.3 billion in 2022, then rose by 2.03% to $13.6 billion in 2023, then surged by 40.42% to $19.1 billion in 2024, then gained by 18.0% to $22.5 billion in 2025, then gained by 3.32% to $23.3 billion in 2026.
• Business Quant data shows REGN's Non-Current Assets at $23.3 billion in Q2 2026, $22.7 billion in Q1 2026, and $22.5 billion in Q4 2025.